AI-driven Drug Discovery
The partnership takes advantage of Insilico's end-to-end AI-driven Pharma.AI platform to find novel small molecule drug candidates for multiple targets, as well as EQRx's innovative business model to speed drug development and provide patients with affordable access to novel medicines.
Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has formed a strategic partnership with EQRx, a company dedicated to developing and delivering innovative medicines to patients at drastically reduced costs.
The collaboration will combine Insilico's Pharma.AI platform to advance de novo small molecule design and generation with EQRx's clinical development and commercialization expertise. EQRx and Insilico will engage in a co-development partnership whereby each party will be eligible for a profit share proportional to its respective level of investment.
Pursuant to the collaboration agreement, the parties will identify and select up to three therapeutics targets leveraging Insilico's AI-driven platform, Pharma. AI. Insilico will lead the drug discovery from small molecule hit identification through lead optimization and preclinical candidate nomination to Investigational New Drug (IND) applicationClinical development, regulatory activities, and commercialization will all be handled by EQRx. Insilico has the option of investing in the product candidate(s) at different stages of clinical development in exchange for higher commercialization profits.
"Both EQRx and Insilico Medicine strive to accelerate the discovery and development of new medicines and make effective therapeutics more accessible and affordable. This partnership will combine our end-to-end AI-powered drug discovery capabilities with EQRx's innovative partnership model and expertise in clinical development and patient access to accelerate the discovery and development of innovative therapies" said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine.
"We are pleased to partner with Insilico Medicine, a leader in AI-based drug discovery," said Carlos Garcia-Echeverria, PhD, chief of Rx Creation at EQRx. "This collaboration will further expand our early-stage R&D efforts to fuel potential pipeline growth as we continue to apply the best of today's innovation in biomedical sciences and digital solutions to discover high-quality, innovative and more affordable medicines."
Note: Content may be edited for style and length.
Reference
